Lexaria Bioscience Corp. (LEXX) Earnings History
Net Loss20 years of earnings data (2006–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Lexaria Bioscience Corp. (LEXX) Earnings Overview
As of June 23, 2026, Lexaria Bioscience Corp. (LEXX) reported trailing twelve-month net income of -$11M, reflecting -40.4% year-over-year growth. The company earned $-0.50 per diluted share over the past four quarters, with a net profit margin of -1686.0%.
Looking at the long-term picture, LEXX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$251,508 in fiscal 2012.
Lexaria Bioscience Corp. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ATAI (-$663M net income, -16142.0% margin), CMPS (-$179M net income), MNMD (-$238M net income), LEXX has outperformed on profitability metrics. Compare LEXX vs ATAI →
LEXX Earnings vs Peers
Earnings metrics vs comparable public companies
LEXX Historical Earnings Data (2006–2025)
20 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$12M | -105.4% | -$12M | $-0.66 | -1686.0% | -1648.0% |
| 2024 | -$6M | +13.0% | -$6M | $-0.47 | -1248.2% | -1226.7% |
| 2023 | -$7M | +8.3% | -$7M | $-1.01 | -2946.4% | -2888.5% |
| 2022 | -$7M | -80.5% | -$7M | $-1.24 | -2846.3% | -2545.4% |
| 2021 | -$4M | -2.4% | -$6M | $-0.92 | -557.2% | -763.8% |
| 2020 | -$4M | +4.0% | -$4M | $-1.42 | -1249.7% | -1311.6% |
| 2019 | -$4M | +37.9% | -$4M | $-1.62 | -1841.5% | -1860.6% |
| 2018 | -$7M | -253.0% | -$7M | $-2.79 | -1523.0% | -1526.3% |
| 2017 | -$2M | -53.9% | -$2M | $-0.95 | -2937.3% | -3022.4% |
| 2016 | -$1M | +31.4% | -$1M | $-0.83 | -2983.4% | -3093.5% |
| 2015 | -$2M | +5.4% | -$2M | $-1.34 | -12042.6% | -13115.3% |
| 2014 | -$2M | -444.7% | $294,057 | $-0.07 | -170.5% | 26.8% |
| 2013 | $-343,551 | -36.6% | $-56,901 | $-0.42 | -31.3% | -5.2% |
| 2012 | $-251,508 | +53.3% | $-13,867 | $-1.09 | -18.5% | -1.0% |
| 2011 | $-538,226 | +2.6% | $-259,500 | $-1.22 | -47.5% | -22.9% |
| 2010 | $-552,462 | +26.7% | $-358,307 | $-2.80 | -152.4% | -98.9% |
| 2009 | $-753,573 | +23.0% | $-488,378 | $-4.46 | -178.6% | -115.7% |
| 2008 | $-978,490 | +7.3% | $-384,609 | $-5.21 | -108.6% | -42.7% |
| 2007 | -$1M | -107.7% | -$1M | $-3.16 | -417.1% | -418.1% |
| 2006 | $-508,256 | - | $-214,974 | $-0.47 | -2502.9% | -1058.6% |
Download Data
Export LEXX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
20+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LEXX — Frequently Asked Questions
Quick answers to the most common questions about buying LEXX stock.
What is LEXX earnings per share (EPS)?
LEXX trailing twelve-month (TTM) diluted EPS is $-0.50, reflecting -40.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2006 to 2025 is available in the table on this page.
What is Lexaria Bioscience Corp.'s net income?
Lexaria Bioscience Corp. (LEXX) trailing twelve-month net income is $-11M as of 2025. Earnings declined -40.4% year-over-year.
Is LEXX profitable?
LEXX is not currently profitable on a TTM basis, reporting a net loss of $-11M. Net margin is -1686.0%. Investors should monitor for a return to profitability.
What is LEXX's earnings growth rate?
LEXX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2006 to 2025.
What are LEXX's profit margins?
Lexaria Bioscience Corp. net profit margin is -1686.0%, operating margin is -1648.0%, and gross margin is +83.2%. Below-average margins reflect competitive or cost pressures. Return on Equity is -232.0%.
Is LEXX growing earnings?
LEXX earnings are declining — EPS fell -40.4% year-over-year. TTM net income dropped to $-11M. This contrasts with the 5-year CAGR of N/A.
What was LEXX's best earnings year?
Lexaria Bioscience Corp.'s highest annual net income on record is $-251508.00, achieved in fiscal year 2012. Earnings history on this page spans 2006 to 2025 and includes all annual and quarterly figures.
What were LEXX's earnings last quarter?
LEXX's most recent reported quarter was Q1 2026. Net income was $-2M with diluted EPS of $-0.07. For a full breakdown of all quarters, see the quarterly earnings table on this page.